498 related articles for article (PubMed ID: 25777966)
1. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
2. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
[TBL] [Abstract][Full Text] [Related]
3. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
[No Abstract] [Full Text] [Related]
4. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.
Rømer MU; Nygård SB; Christensen IJ; Nielsen SL; Nielsen KV; Müller S; Smith DH; Vainer B; Nielsen HJ; Brünner N
Mol Oncol; 2013 Feb; 7(1):101-11. PubMed ID: 23110915
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
[TBL] [Abstract][Full Text] [Related]
7. Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters.
Hashmi AA; Bukhari U; Rizwan R; Faisal F; Kumar R; Malik UA; Zia S; Khan AR; Sham S; Irfan M
Cureus; 2023 Aug; 15(8):e42781. PubMed ID: 37664303
[TBL] [Abstract][Full Text] [Related]
8. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort.
Smith DH; Christensen IJ; Jensen NF; Markussen B; Rømer MU; Nygård SB; Müller S; Nielsen HJ; Brünner N; Nielsen KV
PLoS One; 2013; 8(4):e60613. PubMed ID: 23577133
[TBL] [Abstract][Full Text] [Related]
10. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
11. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Nygård SB; Vainer B; Nielsen SL; Bosman F; Tejpar S; Roth A; Delorenzi M; Brünner N; Budinska E
Clin Cancer Res; 2016 Apr; 22(7):1621-31. PubMed ID: 26542057
[TBL] [Abstract][Full Text] [Related]
12. Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Pedersen MØ; Poulsen TS; Gang AO; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Nørgaard P
Exp Hematol; 2015 Jul; 43(7):534-6. PubMed ID: 25931012
[TBL] [Abstract][Full Text] [Related]
13. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
14. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
[TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
Liu LM; Xiong DD; Lin P; Yang H; Dang YW; Chen G
Int J Oncol; 2018 Nov; 53(5):1897-1912. PubMed ID: 30132517
[TBL] [Abstract][Full Text] [Related]
16. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
17. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
Nygård SB; Christensen IJ; Nielsen SL; Nielsen HJ; Brünner N; Spindler KL
Scand J Gastroenterol; 2014 Jan; 49(1):84-91. PubMed ID: 24256029
[TBL] [Abstract][Full Text] [Related]
19. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
Murthy SK; Magliocco AM; Demetrick DJ
Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
[TBL] [Abstract][Full Text] [Related]
20. Systematic immunohistochemical screening for mismatch repair and ERCC1 gene expression from colorectal cancers in China: Clinicopathological characteristics and effects on survival.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(8):e0181615. PubMed ID: 28767665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
